Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,531 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,531 Papers indexed
1,440 Papers AI scored
39,531 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-10-23 09:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39531 results
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.2/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 23.5; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
Quantitative determination of liposomal irinotecan and SN-38 concentrations in plasma samples from children with solid tumors: Use of a cryoprotectant solution to enhance liposome stability.
PMID 39146822 Published: 2024-08-14 Ingested: 2026-08-02 12:01 AM Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
AI -
Standard 73.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 26.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
Classic Hodgkin lymphoma.
PMID 38037872 Published: 2023-12-01 Ingested: 2026-08-02 12:03 AM Hematological oncology
AI -
Standard 73.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 76.0; sample size: 100.0; recency: 80.0; abstract quality: 65.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 88.4; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
Access to Anticancer Drug Trials for Adolescents With Cancer in the United States.
PMID 42544874 Published: 2026-08-03 Ingested: 2026-08-05 09:15 AM Pediatric blood & cancer
AI -
Standard 73.16
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
Physical Therapy Is an Underutilized Health Resource for Children with Cancer: A Retrospective Study Identifies Facilitators for Improvement.
PMID 41516950 Published: 2025-12-21 Ingested: 2026-08-02 12:05 AM Healthcare (Basel, Switzerland)
AI -
Standard 73.14
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.1/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.2; sample size: 80.0; recency: 100.0; abstract quality: 85.0.

B
National multicentered retrospective review of salvage therapy for pediatric medulloblastoma: a Canadian experience.
PMID 41324672 Published: 2025-12-01 Ingested: 2026-08-02 12:05 AM Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
AI -
Standard 73.14
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 68.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Geographic Access to Cancer Care and Breast Cancer Treatment in Low-Income Women.
PMID 40730348 Published: 2025-07-03 Ingested: 2026-08-02 12:04 AM Medical care
AI -
Standard 73.14
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 58.2; sample size: 90.0; recency: 90.0; abstract quality: 100.0.

B
Risk stratified treatment for childhood acute lymphoblastic leukaemia: a multicentre observational study from India.
PMID 40487914 Published: 2025-05-13 Ingested: 2026-08-02 12:04 AM The Lancet regional health. Southeast Asia
AI -
Standard 73.14
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 58.2; sample size: 90.0; recency: 90.0; abstract quality: 100.0.

B
Ag(e)nostic precision oncology therapy approvals across the years.
PMID 40480903 Published: 2025-06-05 Ingested: 2026-08-02 12:04 AM Trends in cancer
AI -
Standard 73.14
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 43.2; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 58.2; sample size: 90.0; recency: 90.0; abstract quality: 100.0.

B
Impact of Pharmacogenetics on High-Dose Methotrexate Toxicity in Pediatric Oncology.
PMID 40430876 Published: 2025-04-29 Ingested: 2026-08-02 12:04 AM Pharmaceutics
AI -
Standard 73.14
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 73.2; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 472 of 3295
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic